# FT819 in Subjects With B-cell Malignancies

> **NCT04629729** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Fate Therapeutics** · enrollment: 54 (actual)

## Conditions studied

- Lymphoma, B-Cell
- Chronic Lymphocytic Leukemia
- Precursor B-Cell Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** FT819
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** IL-2
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT04629729
- **Lead sponsor:** Fate Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-12
- **Primary completion:** 2025-06-18
- **Final completion:** 2039-09-30
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04629729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04629729, "FT819 in Subjects With B-cell Malignancies". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04629729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*